Active Biotech

The abstract, entitled Preclinical studies demonstrating efficacy of tasquinimod in models of advanced myeloproliferative neoplasm (MPN) in blastic phase, was presented as an oral presentation by Dr. Warren Fiskus, PhD, MD Anderson Cancer Center, TX, USA. The abstract is the result of a collaboration between Active Biotech and Professor Kapil Bhalla’s research group at MD Anderson. The results demonstrate tasquinimod’s efficacy as monotherapy and in combination with approved and investigational therapies in models of advanced MPNs. The positive results create a rationale for a clinical study in patients with myelofibrosis.

In addition, the abstract entitled Tasquinimod improves erythropoiesis and mitigates bone loss in myelodysplastic mice was presented as a poster by Dr. Manja Wobus, University Hospital Dresden, Germany. The abstract comes from our collaboration with Dr Wobus in Dresden, showing the first evidence for an in vivo effect of tasquinimod in a murine model of MDS, by significantly improving red blood cell counts and decreasing bone loss.

Information on the presentations:

P 741 Preclinical Studies Demonstrating Efficacy of Tasquinimod in Models of Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase, Warren Fiskus et al. Session: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Stromal-Immune and Signaling Context, Dec 11, 2023, 10:30 AM - 12:00 PM, San Diego Convention Center, Ballroom 20AB

P 2798 Tasquinimod Improves Erythropoiesis and Mitigates Bone Loss in Myelodysplastic Mice, Manja Wobus et al. Session: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II, Sunday, December 10, 2023, 6:00 PM - 8:00, San Diego Convention Center, Halls G-H

The presentations are now available on Active Biotech’s website. The abstracts are available on the ASH website.